Latest News for: in vivo

Edit

What is an In-vivo tested sunscreen? 7 picks that promise safe and reliable sun protection

Hindustan Times 13 Feb 2026
Do you know that in-vivo ...
Edit

World-First EXO 001 Exosome Platform Enables In Vivo Multi-Target CAR-T for Solid Tumors

PR Newswire 13 Feb 2026
EXO 001 In Vivo CAR-T. World-First Targeted Exosome Platform Enables In Vivo Generation of Multi-Target CAR-T Cells ... In Vivo Immune Programming Overcomes the Limitations of Conventional CAR-T Therapy.
Edit

SynGenSys Introduces Liver.SET Synthetic Promoter Library for Liver-specific Gene Expression for in vivo Gene Therapies

Business Wire 05 Feb 2026
SHEFFIELD, England--(BUSINESS WIRE)--SynGenSys, a biotechnology company designing synthetic gene ...
Edit

Letter from VI Regarding OECD 488 In Vivo Mutagenicity Study on 1,2-Dichloroethane (The eRulemaking Program)

Public Technologies 04 Feb 2026
OECD 488 In Vivo Mutagenicity Study on 1,2-Dichloroethane ... Accompanying the OECD TG 488 study was an in vivo micronucleus assay conducted in accordance with OECD TG 474 and under GLP ... In vivo ...
Edit

CREATE Medicines Demonstrates Complete B Cell Depletion and Repeatable Dosing in Non-human Primates with In Vivo CAR-T Platform

PR Newswire 02 Feb 2026
("CREATE"), a clinical-stage biotechnology company pioneering in vivo CAR therapy, today announced new detailed data demonstrating complete B cell depletion in NHPs using its proprietary in vivo CAR-T platform.
Edit

Clinical Trial Demonstrates Accurate Non-Invasive Detection of In Vivo Biologic Activity in Melanomas by the Orlucent® Skin Fluorescent Imaging System

PR Newswire 20 Jan 2026
SFI detected oncogenic activity in 100% of melanoma cases ... The journal article is available online and is entitled, "In Vivo Molecular Skin Fluorescence Imaging for Non-Invasive Assessment of Atypical Nevi and Melanoma.
Edit

BioNxt Reports Successful Final In-Vivo Dosing Study Results Supporting Superior Bioavailability of Cladribine Sublingual ODF

Pharmiweb 19 Jan 2026
Forward-looking information includes, but is not limited to, statements regarding the Company's cladribine sublingual orally dissolving film ("ODF") program; the interpretation, significance, and ...
Edit

Emerging LNP Technology and mRNA Strategies for In Vivo CAR-T Development, Upcoming Webinar Hosted by Xtalks

PR Newswire 15 Jan 2026
In this free webinar, gain insight into the principles of mRNA and LNP technology and their unique advantages for in vivo CAR T-cell development ... 15, 2026 /PRNewswire/ -- Developing in vivo CAR ...
Edit

Vicarious Surgical Advances Toward Design Freeze with Successful In-Vivo Porcine Lab

The Galveston Daily News 12 Jan 2026
WALTHAM, Mass.--(BUSINESS WIRE)--Jan 12, 2026-- ....
Edit

Tessera Therapeutics Announces FDA Clearance of IND Application for its Lead In Vivo Gene Editing ...

Nasdaq Globe Newswire 12 Jan 2026
... for TSRA-196, its lead in vivo gene editing therapy for alpha-1 antitrypsin deficiency (AATD).
Edit

Vicarious Surgical Advances Toward Design Freeze with Successful In-Vivo Porcine Lab (Vicarious Surgical Inc)

Public Technologies 12 Jan 2026
This marks the Company's first in-vivo animal lab conducted in several years, and the first performed with an integrated system architecture rather than early-stage prototypes, providing critical ...
Edit

A chemogenetic approach for temporal and cell-specific activation of endogenous GPCRs in vivo

PNAS 09 Jan 2026
... transduce diverse physiological effects in different cell types.
Edit

Peer-reviewed study demonstrates LEON’s FR-JET® modular mixer enables stable high-concentration mRNA-LNPs with enhanced in vivo activity

Nasdaq Globe Newswire 09 Jan 2026
... industry sources, can improve biological function in vivo, streamline manufacturing, and improve storage stability.
Edit

Gordian Bio Announces Research Collaboration with Pfizer to Accelerate In Vivo Target Discovery in Obesity

The Eagle-Tribune 08 Jan 2026
SAN FRANCISCO--(BUSINESS WIRE)--Jan 8, 2026-- ... .
Edit

STRM.BIO Raises $8 Million in Series Seed 2 Financing to Advance Non-Viral Gene Delivery Platform for In Vivo Cell Engineering and Gene Therapy

PR Newswire 07 Jan 2026
The company's MV platform for in vivo gene therapy represents a novel, non-viral, cell-derived delivery modality with the potential to overcome many of the key barriers limiting current viral and synthetic in vivo gene delivery systems.

Article Search

tools
×
×
×
×